A new UK drug approval pathway has been criticized for prioritizing industry interests over patient needs and NHS resources, despite its goal of speeding up access to new medicines.
The UK's new drug approval pathway has been designed to accelerate the availability of new medicines, but an expert argues that it ultimately benefits the industry at the expense of patients and the National Health Service (NHS). This pathway aims to align the regulatory review process of the Medicines and Healthcare products Regulatory Agency (MHRA) with the health technology appraisal process of the National Institute for Health and Care Excellence (NICE), allowing for simultaneous decision-making.
However, Huseyin Naci, a researcher at the London School of Economics and Political Science, points out that the MHRA and NICE require different types of evidence. The MHRA focuses on a product's clinical effectiveness and safety, while NICE assesses its comparative effectiveness and long-term value for money. Rather than aligning these evidentiary standards, the new pathway runs two independent processes in parallel, with the goal of synchronizing their conclusions. This approach offers companies earlier revenue and a longer rebate-free window, while the benefits for patients and the NHS are less clear.
Naci acknowledges that earlier access to effective new drugs can be crucial for patients with significant unmet needs. However, he notes that the new pathway expedites all new medicines, regardless of their added therapeutic benefit. In contrast, the Innovative Licensing and Access Pathway (ILAP) is more patient-focused, as it prioritizes medicines that address significant unmet needs. The new pathway will also impose timelines to ensure that MHRA and NICE decisions are reached simultaneously, which may lead to higher rates of adverse events and post-marketing safety issues.
A further concern is that NICE committees may be asked to assess products based on evidence that has not been fully vetted by the MHRA, compounding the uncertainty under which they already operate. The earlier adoption of expensive, potentially low-value medicines will also divert NHS resources away from more cost-effective interventions. This problem is exacerbated by the 2025 US-UK trade agreement, which commits NICE to a 25% higher cost-effectiveness threshold. Naci urges the government to prioritize patient needs and population health in its medicines access policy, calling for clarification on the assumptions underpinning the pathway and an assessment of its anticipated benefits and harms for all stakeholders.
The synchronization of decisions between the MHRA and NICE may overlook the potential risks to the NHS, including the earlier adoption of medicines that prove harmful, ineffective, or poor value. Naci concludes that the government must ground its medicines access policy in patient need and population health, rather than prioritizing industry interests. This requires a more nuanced approach to drug approval, one that balances the need for rapid access to new medicines with the need to protect patients and the NHS from unnecessary risks and costs.
The debate surrounding the new drug approval pathway highlights the complex trade-offs involved in regulating the pharmaceutical industry. While the goal of accelerating access to new medicines is laudable, it must be balanced against the need to ensure that these medicines are safe, effective, and provide value for money. Ultimately, the UK government must prioritize the needs of patients and the NHS, rather than the interests of the pharmaceutical industry. By doing so, it can create a more sustainable and equitable healthcare system that benefits all stakeholders.
